Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 11:15:868531.
doi: 10.3389/fnmol.2022.868531. eCollection 2022.

Gene and Cell Therapy for Epilepsy: A Mini Review

Alisa A Shaimardanova  1 , Daria S Chulpanova  1 , Aysilu I Mullagulova  1 , Zaid Afawi  2 , Rimma G Gamirova  1 , Valeriya V Solovyeva  1 , Albert A Rizvanov  1
Affiliations
Review

Gene and Cell Therapy for Epilepsy: A Mini Review

Alisa A Shaimardanova et al. Front Mol Neurosci. .

Abstract

Epilepsy is a chronic non-infectious disease of the brain, characterized primarily by recurrent unprovoked seizures, defined as an episode of disturbance of motor, sensory, autonomic, or mental functions resulting from excessive neuronal discharge. Despite the advances in the treatment achieved with the use of antiepileptic drugs and other non-pharmacological therapies, about 30% of patients suffer from uncontrolled seizures. This review summarizes the currently available methods of gene and cell therapy for epilepsy and discusses the development of these approaches. Currently, gene therapy for epilepsy is predominantly adeno-associated virus (AAV)-mediated delivery of genes encoding neuro-modulatory peptides, neurotrophic factors, enzymes, and potassium channels. Cell therapy for epilepsy is represented by the transplantation of several types of cells such as mesenchymal stem cells (MSCs), bone marrow mononuclear cells, neural stem cells, and MSC-derived exosomes. Another approach is encapsulated cell biodelivery, which is the transplantation of genetically modified cells placed in capsules and secreting various therapeutic agents. The use of gene and cell therapy approaches can significantly improve the condition of patient with epilepsy. Therefore, preclinical, and clinical studies have been actively conducted in recent years to prove the benefits and safety of these strategies.

Keywords: adeno-associated virus; cell therapy; encapsulated cell biodelivery; epilepsy; gene therapy; mesenchymal stem cells; mononuclear cells; neural stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Methods of administration of gene and cell drugs for epilepsy reported in in vivo and clinical studies.
See this image and copyright information in PMC

References

    1. Abdanipour A., Tiraihi T., Mirnajafi-Zadeh J. (2011). Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell therapy. Neurol. Res. 33 625–632. 10.1179/1743132810Y.0000000018 - DOI - PubMed
    1. Aly R. M. (2020). Current state of stem cell-based therapies: an overview. Stem Cell Investig. 7:8. 10.21037/sci-2020-001 - DOI - PMC - PubMed
    1. Athanasopoulos T., Munye M. M., Yanez-Munoz R. J. (2017). Nonintegrating Gene Therapy Vectors. Hematol. Oncol. Clin. North Am. 31 753–770. 10.1016/j.hoc.2017.06.007 - DOI - PubMed
    1. Baraban S. C., Southwell D. G., Estrada R. C., Jones D. L., Sebe J. Y., Alfaro-Cervello C., et al. (2009). Reduction of seizures by transplantation of cortical GABAergic interneuron precursors into Kv1.1 mutant mice. Proc. Natl. Acad. Sci. U S A 106 15472–15477. 10.1073/pnas.0900141106 - DOI - PMC - PubMed
    1. Benmaamar R., Pham-Le B. T., Marescaux C., Pedrazzini T., Depaulis A. (2003). Induced down-regulation of neuropeptide Y-Y1 receptors delays initiation of kindling. Eur. J. Neurosci. 18 768–774. 10.1046/j.1460-9568.2003.02810.x - DOI - PubMed

LinkOut - more resources